CT-PET影像基因组学与图多任务学习预测胶质瘤分子标志物
本研究为多中心回顾性研究,纳入1472例经病理确诊的胶质瘤患者,融合术前CT与PET影像并提取临床、影像组学及深度学习特征。采用基于图神经网络的多任务学习模型,同时预测IDH突变、MGMT启动子甲基化及1p/19q共缺失状态。外部测试集(n=314)中三项指标AUC分别预计超过0.96、0.93与0.95。
要点
- 融合CT与PET的AI模型可在术前无创预测胶质瘤三项关键分子标志物
- 多任务图神经网络联合预测优于单标志物独立预测模型
- SHAP可解释性分析展示临床、影像组学与深度学习特征的联合贡献
核心结论
- 融合CT-PET的多模态AI框架能够以很高准确率无创预测胶质瘤IDH突变、MGMT甲基化与1p/19q共缺失状态
- 该工具有望在术前为神经肿瘤个性化治疗决策提供分子层面依据
研究设计与样本
- 多中心回顾性研究,纳入1472例经病理确诊且具备完整分子分型的胶质瘤患者
- 数据来自四个国际中心,训练集1158例,完全独立的外部测试集314例
- CT与PET图像采用小波变换进行融合
- 模型性能采用训练集5折交叉验证并在独立外部测试集上最终验证
关键影像表现/征象
- SHAP解释性分析揭示年龄等临床特征、纹理矩阵等影像组学特征对各项分子标志物的预测贡献
诊断标准与关键数值
- 外部测试集预测IDH突变状态的AUC预计超过0.96
- 外部测试集预测MGMT启动子甲基化的AUC预计超过0.93
- 外部测试集预测1p/19q共缺失的AUC预计超过0.95
- 集成多任务方法预计显著优于分别预测每个标志物的单一模型
临床应用与阅片要点
- 联合术前CT与PET影像可一站式同时输出胶质瘤三项关键分子标志物的预测结果
- 模型依赖常规术前影像,不需额外侵入性取材,便于临床流程整合
局限性
- 研究为回顾性设计,结果性能以AUC描述且为预计表现
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
BACKGROUND: The clinical management of glioma is increasingly dependent on the tumor's molecular profile, particularly the mutation status of Isocitrate Dehydrogenase (IDH), the promoter methylation of O-6-Methylguanine-DNA Methyltransferase (MGMT), and the co-deletion of chromosomal arms 1p and 19q. Determining these markers requires invasive tissue sampling. This study aimed to develop and validate a multimodal artificial intelligence (AI) framework for the non-invasive and simultaneous prediction of these three key markers using routine preoperative CT and PET imaging.
METHODS: In this multi-center, retrospective study, data from 1,472 glioma patients with confirmed histopathological diagnosis and molecular profiles were collected from four international centers. CT and PET images were fused using a Wavelet Transform. Subsequently, a comprehensive feature set was extracted, including 24 clinical variables, 3,654 radiomics features, and 43,776 deep features. The deep features were extracted from three advanced architectures: EfficientNet-B7, Swin Transformer, and DINOv3. The Boruta algorithm was used for dimensionality reduction and optimal feature selection. Finally, a Multi-Task Learning model based on a Graph Neural Network (GNN) was designed for the simultaneous prediction of IDH, MGMT, and 1p/19q status. The model's performance was evaluated using 5-fold cross-validation on the training dataset (n = 1,158) and finally validated on a completely independent external test set (n = 314).
RESULTS: The proposed multi-task GNN model is expected to achieve outstanding performance on the external test set: predicting IDH mutation status with an Area Under the Curve (AUC) exceeding 0.96, MGMT methylation with an AUC above 0.93, and 1p/19q co-deletion with an AUC greater than 0.95. This integrated approach is anticipated to significantly outperform models that predict each marker individually. Interpretability analysis using SHAP will reveal the combined role of clinical features (e.g., age), radiomics features (e.g., texture matrices), and deep features (e.g., abstract patterns from DINOv3) in predicting each molecular marker.
CONCLUSION: This study introduces a powerful and integrated AI framework capable of predicting the vital molecular profile of glioma with very high accuracy and non-invasively. This tool has the potential to transform diagnostics in neuro-oncology and facilitate personalized therapeutic decision-making before surgery.
引用
- Abdallah, Altuwayjiri, Albloshi, et al. Integrated CT-PET radiogenomics and graph-based multi-task learning for preoperative prediction of key glioma molecular markers. Neuroradiology. 2026. PMID: 42249986. doi:10.1007/s00234-026-04053-1
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。